Expert Interview
Examining the potential of Equillium's Itolizumab in treating lupus nephritis
Ticker(s): EQInstitution: Harvard
- Clinical Professor of Medicine at Harvard Medical School and Founding Director of the Dialysis and Transplantation Program at Beth Israel Hospital in Boston.
- Involved in PKD clinical research since the early 1980s, starting with the MDRD study with a focus on pain management in PKD.
- Continuous kidney research since 1970 has resulted in 180 peer-reviewed publications, 30 book chapters, 187 Proceedings and 146 abstracts.
Please describe your background and practice setting
Added By: ben_adminHow many patients with Lupus Nephritis do you currently manage?
Added By: ben_adminCan you describe the disease journey of these patients?
Added By: ben_adminHow are patients currently managed? Is there an unmet need?
Added By: ben_adminWhat do you think about the EQUALISE trial and the potential of Itolizumab in this space?
Added By: ben_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
